{"id":745537,"date":"2017-06-04T09:00:00","date_gmt":"2017-06-04T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/"},"modified":"2025-11-07T01:26:27","modified_gmt":"2025-11-07T06:26:27","slug":"new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/","title":{"rendered":"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced findings from Cohort 1 of the phase 2 registrational<br \/>\n      KEYNOTE-059 trial investigating KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab),<br \/>\n      the company\u2019s anti-PD-1 therapy, as monotherapy in previously-treated<br \/>\n      patients with advanced gastric or gastroesophageal junction<br \/>\n      adenocarcinoma. Results showed an overall response rate (ORR) of 11.6<br \/>\n      percent (95% CI, 8.0-16.1) in patients treated with KEYTRUDA who had<br \/>\n      received two or more prior lines of treatment, with higher response<br \/>\n      rates among patients with PD-L1 positive tumors. The results will be<br \/>\n      presented at the 2017 American Society of Clinical Oncology (ASCO)<br \/>\n      Annual Meeting in Chicago in an oral presentation on Sunday, June 4 from<br \/>\n      9:00 &#8211; 9:12 a.m. CDT (Location: Hall D2) (Abstract #4003).\n    <\/p>\n<p>\n      Data from this Cohort support Merck\u2019s supplemental Biologics License<br \/>\n      Application (sBLA) for KEYTRUDA \u2013 currently under Priority Review with<br \/>\n      the U.S. Food and Drug Administration (FDA) \u2013 seeking approval for the<br \/>\n      treatment of patients with recurrent or advanced gastric or<br \/>\n      gastroesophageal junction adenocarcinoma who have already received two<br \/>\n      or more lines of chemotherapy.\n    <\/p>\n<p>\n      \u201cAdvanced gastric cancer is difficult to treat and there is a<br \/>\n      significant need to identify new treatment options for these patients,\u201d<br \/>\n      said Charles S. Fuchs, M.D., MPH, lead investigator and director of Yale<br \/>\n      Cancer Center. \u201cThe findings from this study showed meaningful response<br \/>\n      rates for KEYTRUDA in heavily pre-treated patients, who have<br \/>\n      historically faced poor outcomes.\u201d\n    <\/p>\n<p>\n      \u201cThe data we are observing from this trial are encouraging as they<br \/>\n      demonstrate the potential for KEYTRUDA to address the serious unmet need<br \/>\n      that currently exists for patients with advanced gastric cancer,\u201d said<br \/>\n      Dr. Roger Dansey, senior vice president and therapeutic area head,<br \/>\n      oncology late-stage development, Merck Research Laboratories.\n    <\/p>\n<p>\n      Merck is committed to investigating new approaches across the spectrum<br \/>\n      of cancers with more than 500 clinical trials evaluating KEYTRUDA<br \/>\n      (pembrolizumab) in more than 30 tumor types \u2013 including multiple<br \/>\n      gastrointestinal disorders, such as gastric or gastroesophageal cancers<br \/>\n      and MSI-H colorectal cancer, among others. Specific to gastric cancer,<br \/>\n      Merck\u2019s\u00a0broad clinical development program encompasses all stages of<br \/>\n      advanced disease and is investigating KEYTRUDA as monotherapy and in<br \/>\n      combination with other cancer treatments across multiple lines of<br \/>\n      therapy. To date, the program includes four gastric cancer<br \/>\n      registration-enabling studies and numerous other gastrointestinal cancer<br \/>\n      studies are underway.\n    <\/p>\n<p>\n      <b>Key Findings from KEYNOTE-059 Cohort 1<\/b>\n    <\/p>\n<p>\n      KEYNOTE-059 is a registrational, phase 2 non-randomized, multi-cohort<br \/>\n      study investigating KEYTRUDA in patients with advanced gastric or<br \/>\n      gastroesophageal junction adenocarcinoma. In patients who received at<br \/>\n      least two prior chemotherapies (Cohort 1), KEYTRUDA is being<br \/>\n      investigated as a monotherapy (200 mg every three weeks for up to 24<br \/>\n      months). The primary endpoints are ORR as assessed by Blinded<br \/>\n      Independent Central Review (BICR) using Response Evaluation Criteria in<br \/>\n      Solid Tumors (RECIST) v1.1 and safety; secondary endpoints include<br \/>\n      duration of response and overall survival. Data were further assessed<br \/>\n      based on PD-L1 expression; tumors were considered to have positive PD-L1<br \/>\n      expression if the combined positive score (CPS) \u2013 as examined by tumor<br \/>\n      and immune cells \u2013 was equal to or greater than one.\n    <\/p>\n<p>\n      The efficacy analysis in all patients (n=259) showed an ORR of 11.6<br \/>\n      percent (95% CI, 8.0- 16.1) \u2013 with a complete response rate of 2.3<br \/>\n      percent (95% CI, 0.9-5.0) and a partial response rate of 9.3 percent<br \/>\n      (95% CI, 6.0-13.5). Data were further analyzed based on PD-L1<br \/>\n      expression. In patients whose tumors expressed PD-L1 (CPS \u22651%) (n=148),<br \/>\n      the ORR was 15.5 percent (95% CI, 10.1-22.4) \u2013 with a complete response<br \/>\n      rate of two percent (95% CI, 0.4-5.8) and a partial response rate of<br \/>\n      13.5 percent (95% CI, 8.5-20.1). In PD-L1 negative patients (n=109), the<br \/>\n      ORR was 6.4 percent (95% CI, 2.6-12.8) \u2013 with a complete response rate<br \/>\n      of 2.8 percent (95% CI, 0.6-7.8) and a partial response rate of 3.7<br \/>\n      percent (95% CI, 1.0-9.1).\n    <\/p>\n<p>\n      Analyses based on prior lines of therapy showed that in patients who<br \/>\n      received two lines of prior chemotherapy (third-line treatment setting;<br \/>\n      n=134), the ORR was 16.4 percent (95% CI, 10.6-23.8) \u2013 with a complete<br \/>\n      response rate of 3.0 percent (95% CI, 0.8-7.5) and a partial response<br \/>\n      rate of 13.4 percent (95% CI, 8.2-20.4). In patients who had received<br \/>\n      three lines of prior chemotherapy (fourth-line treatment setting;<br \/>\n      n=125), the ORR was 6.4 percent (95% CI, 2.8-12.2) \u2013 with a complete<br \/>\n      response rate of 1.6 percent (95% CI, 0.2-5.7) and a partial response<br \/>\n      rate of 4.8 percent (95% CI, 1.8-10.2).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported studies. The treatment-related adverse<br \/>\n      events (any grade occurring in 5% or more of patients) were fatigue<br \/>\n      (18.9%), pruritus (8.9%), rash (8.5%), hypothyriodism (7.7%), decreased<br \/>\n      appetite (7.3%), anemia (6.9%), nausea (6.9%), diarrhea (6.6%), and<br \/>\n      arthralgia (5.8%). Grade 3-4 treatment-related adverse events observed<br \/>\n      (in all patients) were anemia (2.7%), fatigue (2.3%), diarrhea (1.2%),<br \/>\n      rash (0.8%), nausea (0.8%), hypothyroidism (0.4%), and arthralgia<br \/>\n      (0.4%). Two patients discontinued treatment due to treatment-related<br \/>\n      adverse events (abnormal hepatic function and bile duct stenosis); Grade<br \/>\n      5 treatment-related adverse events occurred in two patients (acute<br \/>\n      kidney injury and pleural effusion). Immune-mediated adverse events of<br \/>\n      Grade 3-4 occurred in 4.6 percent or less of patients and included:<br \/>\n      colitis, pneumonitis, thyroiditis, hypothyroidism, and severe skin<br \/>\n      reactions.\n    <\/p>\n<p>\n      <b>About Gastric Cancer<\/b>\n    <\/p>\n<p>\n      Gastric cancer, also called stomach cancer, is a type of cancer that<br \/>\n      begins in the stomach and tends to develop slowly over many years. Most<br \/>\n      gastric cancers are adenocarcinomas, which develop from the cells of the<br \/>\n      innermost lining (mucosa) of the stomach. Risk factors for gastric<br \/>\n      cancer include gender, age, ethnicity, geography and infection with <i>Helicobacter<br \/>\n      pylori<\/i>. Worldwide, gastric cancer is the fifth most common type of<br \/>\n      cancer and the third leading cause of cancer death. Each year there are<br \/>\n      approximately 952,000 newly diagnosed cases of gastric cancer resulting<br \/>\n      in approximately 723,000 deaths worldwide. It is estimated that in 2017,<br \/>\n      more than 10,000 people will die from gastric cancer in the U.S. alone.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA (pembrolizumab)<br \/>\n      for injection is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA<br \/>\n      (pembrolizumab) is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression, unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA (pembrolizumab) in pediatric patients with<br \/>\n      MSI-H central nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>\u00a0<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA (pembrolizumab) for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider the<br \/>\n      benefit of treatment with KEYTRUDA vs the risk of possible organ<br \/>\n      rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%).The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs<br \/>\n      50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%),<br \/>\n      vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%),<br \/>\n      decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs<br \/>\n      18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients<br \/>\n      with cHL, and treatment was interrupted due to adverse reactions in 26%<br \/>\n      of patients. Fifteen percent (15%) of patients had an adverse reaction<br \/>\n      requiring systemic corticosteroid therapy. Serious adverse reactions<br \/>\n      occurred in 16% of patients. The most frequent serious adverse reactions<br \/>\n      (\u22651%) included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and<br \/>\n      herpes zoster. Two patients died from causes other than disease<br \/>\n      progression; one from GVHD after subsequent allogeneic HSCT and one from<br \/>\n      septic shock. The most common adverse reactions (occurring in \u226520% of<br \/>\n      patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA (pembrolizumab) was discontinued due to adverse<br \/>\n      reactions in 11% of 370 patients with locally advanced or metastatic<br \/>\n      urothelial carcinoma. The most common adverse reactions (in \u226520% of<br \/>\n      patients) were fatigue (38%), musculoskeletal pain (24%), decreased<br \/>\n      appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).<br \/>\n      Eighteen patients (5%) died from causes other than disease progression.<br \/>\n      Five patients (1.4%) who were treated with KEYTRUDA experienced sepsis<br \/>\n      which led to death, and 3 patients (0.8%) experienced pneumonia which<br \/>\n      led to death. Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 22% of patients; the most common (\u22651%) were liver enzyme<br \/>\n      increase, diarrhea, urinary tract infection, acute kidney injury,<br \/>\n      fatigue, joint pain, and pneumonia. Serious adverse reactions occurred<br \/>\n      in 42% of patients, the most frequent (\u22652%) of which were urinary tract<br \/>\n      infection, hematuria, acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA<br \/>\n      (pembrolizumab)-treated patients, the most frequent (\u22652%) of which were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue, pruritus, diarrhea, decreased appetite, rash, pyrexia, cough,<br \/>\n      dyspnea, musculoskeletal pain, constipation, and nausea.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=e40acd98b07013bf296bdd4df136b951\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=eb82b9207793535805c5eb34b3bbc545\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=e68fc85c00a0b4ac4e6521b5436eb131\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=a2ec5d5b25fb19168695e6fa802eb5b4\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=25a463ef2ca9a687995800623a9ce7fd\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=7c7397c4cdafe31d39fd224acde8d5aa\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=a39fe68ab197a482e9b453cea112e694\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=a075a8da9119f6126ad8c6afb4174ecc\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=f44ac79db7e416282131e679d8d962ac\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>\u00a0and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at\u00a0<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569386&amp;newsitemid=20170604005039&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=a631aec37d23602666a237aa3cc35c19\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170604005039r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/> Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Ann        Bush, 908-740-6677<br \/>or<br \/> Investors: <br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as monotherapy in previously-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Results showed an overall response rate (ORR) of 11.6 percent (95% CI, 8.0-16.1) in patients treated with KEYTRUDA who had received two or more prior lines of treatment, with higher response rates among patients with PD-L1 positive tumors. The results will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in an oral presentation on Sunday, June 4 from 9:00 &#8211; 9:12 a.m. CDT (Location: Hall D2) (Abstract #4003). Data from this Cohort support Merck\u2019s supplemental Biologics License Application (sBLA) for KEYTRUDA \u2013 currently under Priority Review with the U.S. Food and Drug Administration (FDA) \u2013 seeking<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745537","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as monotherapy in previously-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Results showed an overall response rate (ORR) of 11.6 percent (95% CI, 8.0-16.1) in patients treated with KEYTRUDA who had received two or more prior lines of treatment, with higher response rates among patients with PD-L1 positive tumors. The results will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in an oral presentation on Sunday, June 4 from 9:00 - 9:12 a.m. CDT (Location: Hall D2) (Abstract #4003). Data from this Cohort support Merck\u2019s supplemental Biologics License Application (sBLA) for KEYTRUDA \u2013 currently under Priority Review with the U.S. Food and Drug Administration (FDA) \u2013 seeking\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\\\/\",\"name\":\"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-04T09:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from Cohort 1 of the phase 2 registrational KEYNOTE-059 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, as monotherapy in previously-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Results showed an overall response rate (ORR) of 11.6 percent (95% CI, 8.0-16.1) in patients treated with KEYTRUDA who had received two or more prior lines of treatment, with higher response rates among patients with PD-L1 positive tumors. The results will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in an oral presentation on Sunday, June 4 from 9:00 - 9:12 a.m. CDT (Location: Hall D2) (Abstract #4003). Data from this Cohort support Merck\u2019s supplemental Biologics License Application (sBLA) for KEYTRUDA \u2013 currently under Priority Review with the U.S. Food and Drug Administration (FDA) \u2013 seeking","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:27+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/","name":"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-04T09:00:00+00:00","dateModified":"2025-11-07T06:26:27+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-monotherapy-data-for-mercks-keytruda-pembrolizumab-in-heavily-pre-treated-patients-with-advanced-gastric-cancer-to-be-presented-at-2017-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Monotherapy Data for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"bde5a0c4-e08e-4925-8037-03ad347c1674","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745537\/revisions"}],"predecessor-version":[{"id":3674892,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745537\/revisions\/3674892"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745537"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}